4.6 Article

Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus

Journal

VIRUSES-BASEL
Volume 13, Issue 2, Pages -

Publisher

MDPI
DOI: 10.3390/v13020234

Keywords

thapsigargin; inhibitor; antiviral; SARS-CoV-2; coronavirus OC43; respiratory syncytial virus; influenza virus; broad-spectrum; innate immunity; mouse; remdesivir; ribavirin; oseltamivir

Categories

Funding

  1. Egyptian Ministry of Higher Education and Scientific Research PhD scholarship
  2. Biotechnology and Biological Sciences Research Council (UK) Doctoral Training Programme 2 [BB/M008770/1]
  3. Medical Research Council Confidence in Concept scheme [MC_PC_18058]
  4. University of Nottingham
  5. National Key Research and Development Program of China [2016YFD0500204]
  6. UK Department for Environment, Food & Rural Affairs (DEFRA)
  7. devolved Scottish and Welsh administrations [SV3700]
  8. European Union [871029]
  9. MRC [MC_PC_18058] Funding Source: UKRI

Ask authors/readers for more resources

Thapsigargin (TG) has shown potent antiviral activity against various respiratory viruses, including RSV, OC43, SARS-CoV-2, and influenza virus, with superior performance compared to existing drugs like remdesivir. This broad-spectrum inhibitor also demonstrated lasting antiviral effects and protection against lethal influenza virus challenge in mice.
The long-term control strategy of SARS-CoV-2 and other major respiratory viruses needs to include antivirals to treat acute infections, in addition to the judicious use of effective vaccines. Whilst COVID-19 vaccines are being rolled out for mass vaccination, the modest number of antivirals in use or development for any disease bears testament to the challenges of antiviral development. We recently showed that non-cytotoxic levels of thapsigargin (TG), an inhibitor of the sarcoplasmic/endoplasmic reticulum (ER) Ca2+ ATPase pump, induces a potent host innate immune antiviral response that blocks influenza A virus replication. Here we show that TG is also highly effective in blocking the replication of respiratory syncytial virus (RSV), common cold coronavirus OC43, SARS-CoV-2 and influenza A virus in immortalized or primary human cells. TG's antiviral performance was significantly better than remdesivir and ribavirin in their respective inhibition of OC43 and RSV. Notably, TG was just as inhibitory to coronaviruses (OC43 and SARS-CoV-2) and influenza viruses (USSR H1N1 and pdm 2009 H1N1) in separate infections as in co-infections. Post-infection oral gavage of acid-stable TG protected mice against a lethal influenza virus challenge. Together with its ability to inhibit the different viruses before or during active infection, and with an antiviral duration of at least 48 h post-TG exposure, we propose that TG (or its derivatives) is a promising broad-spectrum inhibitor against SARS-CoV-2, OC43, RSV and influenza virus.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available